Catalytically distinct states captured in a crystal lattice: the substrate-bound and scavenger states of acylaminoacyl peptidase and their implications for functionality

Acta Crystallographica. Section D, Biological Crystallography
Dóra K MenyhárdVeronika Harmat

Abstract

Acylaminoacyl peptidase (AAP) is an oligopeptidase that only cleaves short peptides or protein segments. In the case of AAP from Aeropyrum pernix (ApAAP), previous studies have led to a model in which the clamshell-like opening and closing of the enzyme provides the means of substrate-size selection. The closed form of the enzyme is catalytically active, while opening deactivates the catalytic triad. The crystallographic results presented here show that the open form of ApAAP is indeed functionally disabled. The obtained crystal structures also reveal that the closed form is penetrable to small ligands: inhibitor added to the pre-formed crystal was able to reach the active site of the rigidified protein, which is only possible through the narrow channel of the propeller domain. Molecular-dynamics simulations investigating the structure of the complexes formed with longer peptide substrates showed that their binding within the large crevice of the closed form of ApAAP leaves the enzyme structure unperturbed; however, their accessing the binding site seems more probable when assisted by opening of the enzyme. Thus, the open form of ApAAP corresponds to a scavenger of possible substrates, the actual cleavage of which only takes pl...Continue Reading

References

Apr 20, 1967·Biochemical and Biophysical Research Communications·I Schechter, A Berger
Mar 17, 2000·Biochimica Et Biophysica Acta·T FujinoH Yasuda
Jan 3, 2001·Acta Crystallographica. Section D, Biological Crystallography·M D WinnG N Murshudov
Mar 28, 2002·Cellular and Molecular Life Sciences : CMLS·L Polgár
Sep 14, 2002·The Journal of Biological Chemistry·Zoltán SzeltnerLászló Polgár
Dec 12, 2002·Chemical Reviews·James C PowersKaren Ellis James
Dec 17, 2002·Nature Structural Biology·Hanne B RasmussenNicolai Wagtmann
Apr 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Michael EngelHans Brandstetter
May 3, 2003·Biochemical and Biophysical Research Communications·Kei ShimizuKiyomi Kikugawa
Oct 7, 2004·Biochemical and Biophysical Research Communications·Kei ShimizuKiyomi Kikugawa
Mar 2, 2005·Proceedings of the National Academy of Sciences of the United States of America·Lu ShanChaitan Khosla
Jan 11, 2007·The Journal of Chemical Physics·Giovanni BussiMichele Parrinello
Mar 24, 2009·Biochimica Et Biophysica Acta·Zoltán SzeltnerLászló Polgár
Jul 25, 2009·Molecular Neurodegeneration·Rina YaminCarmela R Abraham
Jan 9, 2010·Acta Crystallographica. Section D, Biological Crystallography·Vincent B ChenDavid C Richardson
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Wolfgang Kabsch
Apr 13, 2010·Acta Crystallographica. Section D, Biological Crystallography·P EmsleyK Cowtan
May 7, 2010·The Journal of Biological Chemistry·Min LiThang K Chiu
Nov 19, 2010·The Journal of Biological Chemistry·Veronika HarmatLászló Polgár
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·Martyn D WinnKeith S Wilson
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·Garib N MurshudovAlexei A Vagin
May 17, 2011·Nature Chemical Biology·Alexander AdibekianBenjamin F Cravatt
Jun 10, 2011·PLoS Biology·Gabriella M A ForteColin J Stirling

❮ Previous
Next ❯

Citations

Sep 26, 2019·Current Protein & Peptide Science·Anna J Kiss-SzemánDóra K Menyhárd

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.